ATHENA- Placebo-controlled Phase 3 in Ovarian Cancer evaluating Rucaparib and Nivolumab
MD Anderson Study Status
Rucaparib, Nivolumab, Placebo Oral Tablet, Placebo IV Infusion
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.